瑞舒伐他汀与阿托伐他汀对急性心肌梗死患者PCI术后左室重构及近期预后影响的比较

被引:65
作者
吴萃荣 [1 ]
王湛 [2 ]
机构
[1] 广东省深圳中海医院内科
[2] 广东省深圳市罗湖区人民医院心内科
关键词
心肌梗死; 瑞舒伐他汀; 阿托伐他汀; 左室重构; 预后;
D O I
暂无
中图分类号
R542.22 [];
学科分类号
摘要
目的:观察比较瑞舒伐他汀与阿托伐他汀对急性心肌梗死患者行经皮冠状动脉介入术(PCI)后左室重构及近期预后的影响。方法:选择80例急性心肌梗死并行PCI术治疗的患者为研究对象,随机分为瑞舒伐他汀组40例和阿托伐他汀组40例,两组患者均在PCI术前后给予抗凝、抗血小板凝聚、扩管等常规治疗,瑞舒伐他汀组患者术后加服瑞舒伐他汀片10 mg/d,阿托伐他汀组患者术后加服阿托伐他汀片20 mg/d,连续治疗并随访12个月。观察两组PCI术后第1天及12个月后的左室舒张末期内径(LVEDD)、左室射血分数(LVEF)、左室质量指数(LVMI)及12个月内发生心血管不良事件(MACE)的比率。结果:两组他汀药物治疗12个月后的LVEDD、LVMI较治疗前明显下降,LVEF则明显升高,瑞舒伐他汀组的相应变化更为显著,两组比较差异有统计学意义(P<0.05)。同时,瑞舒伐他汀组12个月内发生心血管不良事件的比率明显低于阿托伐他汀组,两组比较差异有统计学意义(P<0.05)。结论:瑞舒伐他汀较阿托伐他汀对急性心肌梗死患者PCI术后的左室重构有更强的改善和逆转作用,对近期预后有更好的影响。
引用
收藏
页码:470 / 472
页数:3
相关论文
共 8 条
[1]
急性心肌梗死患者直接PCI术前后炎性细胞因子动态变化的研究 [J].
梁艳媚 ;
林琼申 ;
陈力 .
中国医药导刊, 2011, (04) :647-649
[2]
他汀类药物非降脂作用研究现状 [J].
赵水平 .
医学临床研究, 2004, (01) :1-2
[3]
Efficacy of Atorvastatin Reload in Patients on Chronic Statin Therapy Undergoing Percutaneous Coronary Intervention.[J].Germano Di Sciascio;Giuseppe Patti;Vincenzo Pasceri;Achille Gaspardone;Giuseppe Colonna;Antonio Montinaro.Journal of the American College of Cardiology.2009, 6
[4]
Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention.[J].Giuseppe Patti;Vincenzo Pasceri;Giuseppe Colonna;Marco Miglionico;Dionigi Fischetti;Gennaro Sardella;Antonio Montinaro;Germano Di Sciascio.Journal of the American College of Cardiology.2007, 12
[5]
Statin therapy is associated with lower mortality among patients with severe heart failure [J].
Mozaffarian, D ;
Nye, R ;
Levy, WC .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (09) :1124-1129
[6]
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin ; simvastatin ; and pravastatin across doses (STELLAR * * STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial).[J].Peter H Jones;Michael H Davidson;Evan A Stein;Harold E Bays;James M McKenney;Elinor Miller;Valerie A Cain;James W Blasetto.The American Journal of Cardiology.2003, 2
[7]
Left ventricular remodeling after primary coronary angioplasty - Patterns of left ventricular dilation and long-term prognostic implications [J].
Bolognese, L ;
Neskovic, AN ;
Parodi, G ;
Cerisano, G ;
Buonamici, P ;
Santoro, GM ;
Antoniucci, D .
CIRCULATION, 2002, 106 (18) :2351-2357
[8]
Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction [J].
Hayashidani, S ;
Tsutsui, H ;
Shiomi, T ;
Suematsu, N ;
Kinugawa, S ;
Ide, T ;
Wen, J ;
Takeshita, A .
CIRCULATION, 2002, 105 (07) :868-873